Overview

Safety and Efficacy Study of Catioprost® (Unpreserved Latanoprost 0.005% Emulsion) Compared to Travatan Z® to Treat Glaucoma and Ocular Surface Disease

Status:
Completed

Trial end date:
2011-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare: - the effect of Catioprost® and Travatan Z® on the ocular surface disease (OSD) in subjects with glaucoma or ocular hypertension and ocular surface disease. - the intraocular pressure (IOP) lowering effect and safety of Catioprost® and Travatan Z® in subjects with glaucoma or ocular hypertension and ocular surface disease.

Phase:

Phase 2

Details

Lead Sponsor:

Santen SAS

Treatments:

Latanoprost
Travoprost